KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 FY2027 earnings call

• Clinical Impact & Product Differentiation: Highlighted a case where the AssureWCD system recorded >120 diverted therapies in one night, enabling Heart Alert Services to intervene and airlift a patient to specialized care, demonstrating the value of the integrated care model.
• AI & Automation Strategy: Prioritizing three AI initiatives: (1) Patient support/adherence via automated outreach, (2) Revenue access/collections automation to improve conversion rates, and (3) Commercial demand acceleration to boost sales rep productivity (fittings per rep) without proportional headcount increases.
• Commercial Execution: Splitting high-volume platinum territories to add clinical account specialists, resulting in faster ramp times for new reps and deeper penetration in existing accounts. Newer reps are outperforming prior cohorts due to enhanced training.
• Market Expansion: The WCD market grew ~14% dollar-wise in the 12 months ending July 2026. Kestra holds approximately 15% US market share. Significant under-penetration remains, with 6/7 indicated patients historically unprotected.
• Payer Access: In-network mix improved from ~70% at IPO to low 80s currently. A major national payer recently expanded coverage to non-ischemic patients, signaling positive impact of clinical evidence on policy.
• R&D Pipeline: Progressing partnership with BioV for non-invasive blood pressure monitoring into the Assure platform. Completing late-stage R&D project expected to launch new first-in-category capabilities next quarter.

Revenue for the first quarter of fiscal 2027 was $31 million, representing a 60% year-over-year increase. Gross margin expanded to 56.5%, an improvement of over 10 percentage points year-over-year and 175 basis points sequentially. This marks the 11th consecutive quarter of sequential gross margin expansion. The company operates primarily in the Wearable Cardioverter Defibrillator (WCD) segment; specific revenue contribution percentages for other product segments were not disclosed as the WCD platform constitutes the core business.

• Raised Full-Year FY2027 Revenue Guidance to $141 million, implying 48% growth vs. prior guidance of $137 million.
• Maintained expectation that second-half revenue will accelerate relative to the first half, driven by the ramp-up of reps hired in late FY26 and early FY27.
• Confirmed long-term gross margin target is now mid-70s within the next few years (up from previous 70% target), driven by volume leverage, cost improvements, and higher in-network mix.
• Projected FY2027 GAAP Operating Expenses at $220 million, reflecting continued commercial investment but anticipating R&D spend normalization in H2.

• Execution Risk on AI/Automation: Success depends on effective implementation of AI tools to bend the operating expense curve; failure could lead to disproportionate G&A headcount growth with volume.
• Payer Coverage Uncertainty: While progress is being made, a long tail of regional/local payers remains, and reimbursement rates vary significantly based on in-network status.
• Competitive Pressure: Incumbent competitors are actively investing in market education and expansion, which could slow Kestra’s share gains or market growth rate.
• Regulatory/Compliance: Ongoing need to maintain compliance with federal supply schedules and evolving healthcare regulations as the company scales.

Q: Analyst asked why guidance was raised by more than the beat and about the cadence. / A: Management cited strong KPI trends in prescriptions, in-network mix, and RCM. They expect H2 acceleration due to rep hiring from FY26/27 ramping up and territory splits driving deeper penetration.

Q: Analyst questioned the confidence behind raising gross margin targets to mid-70s. / A: Confidence stems from 11 quarters of expansion, supplier volume-based cost reductions, higher revenue per fit from in-network mix, and proven unit economics inherent in the rental model.

Q: Analyst sought details on the new pipeline product/BioBeat. / A: Management declined to disclose specifics yet, stating they will provide more depth next quarter. They emphasized leveraging the existing platform to add unique capabilities not present in current WCD offerings.

Q: Analyst asked if the large payer covering non-ischemic patients was a first-mover. / A: Brian Webster clarified this payer was an outlier among large insurers who already covered this group. However, it signals that clinical evidence is influencing policy, encouraging optimism for other regional payers.

Q: Analyst inquired about R&D spending cadence and AI impact timing. / A: R&D spend is elevated this year to finalize a multi-year program, with expectations to normalize to 5-7% of revenue in H2. AI benefits on operating margins are starting to appear but will accelerate in FY28-29 as technology stacks scale.